ClinicalTrials.gg
RecruitingNCT06405464Updated May 8, 2024

Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures

An observational study in HIV Infections, sponsored by University of Zurich. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-08.

Sponsored by University of Zurich · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Mar 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
600
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in HIV Infections with a site in Switzerland — 4 open to participants now, 6 under way, 3 of them phase 3. HIV Infections · Switzerland.

Planned enrollment
6th of 17
600 · median 249
Started
2022
the only one that year
Observational
17 of 81
2 open now
Registered
78th of 81
by date
Lead sponsor
5 of 81
University of Zurich

Among the 81 studies in HIV Infections with a site in Switzerland, this one is the 6th largest by planned enrollment of the 17 observational ones that give a count, is the only one that started in 2022, is one of 17 observational ones, and was the 78th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

4 of the 81 studies in HIV Infections with a site in Switzerland are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in HIV Infections with a site in Switzerland, or all of them as a file.
02

Study summary

This study aims to characterize Swiss HIV Cohort Study participants initiating the CAB+RPV LA regimen, assess adherence to Swiss label indications, and describe treatment outcomes in this large, multicentre, heterogeneous, high-income setting. Moreover, the study aims to assess virological, immunological, demographic, clinical, and behavioural factors associated with viral failure under CAB+RPV LA regimen.

03

Conditions studied

  • HIV Infections

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of SHCS participants initiating the CAB+RPV LA regimen and a matched control population on a SOC oral regimen (including dual drug regimens)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant in the SHCS
  • All SHCS participants initiating the CAB+RPV LA regimen
  • All SHCS participants on SOC oral regimen

Exclusion criteria

Exclusion Criteria:

  • Not participating in the SHCS
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
600 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Swiss HIV Cohort Study participants on CAB+RPV LA regimen

    Swiss HIV Cohort Study participants initiating the CAB+RPV LA regimen

    Drug: VOCABRIA 30Mg Tablet · Drug: EDURANT 25Mg Tablet · Drug: Cabotegravir Injectable Suspension · Drug: Rilpivirine Injectable Suspension · Biological: Intact proviral DNA assay · Biological: Full-length sequencing

  • Swiss HIV Cohort Study participants on a standard of care oral regimen

    Matched control population on a standard of care oral regimen

    Biological: Intact proviral DNA assay · Biological: Full-length sequencing

Interventions

  • DrugCabotegravirStudies of CabotegravirCabotegravir pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    CAB 30 mg Film-coated tablets

    Also known as: Cabotegravir Tablets

  • DrugRilpivirineStudies of RilpivirineRilpivirine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    RPV 25 mg film-coated tablets

    Also known as: Rilpivirine Tablets

  • DrugCabotegravirStudies of CabotegravirCabotegravir pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    CAB LA 600 mg prolonged release suspension for injection (3 mL)

    Also known as: Vocabria

  • DrugRilpivirineStudies of RilpivirineRilpivirine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    RPV LA 900 mg prolonged release suspension for injection (3 mL)

    Also known as: Rekambys

  • BiologicalIntact proviral DNA assay

    HIV-1 latent reservoir size

  • BiologicalFull-length sequencing

    Proviral DNA

06

What researchers measure

Primary outcomes

  1. Proportion of individuals with viral blips

    Proportion of individuals with viral blips (defined as one HIV-1 RNA \>50 and \<400 c/mL with a next HIV-1 RNA \<50 copies/ml)

    Time frame: Month 24

  2. Proportion of individuals with confirmed viral failures

    Proportion of individuals with confirmed viral failures (defined as two consecutive HIV-1 RNA ≥ 50 c/mL)

    Time frame: Month 24

  3. Proportion of individuals switching off CAB+RPV LA to previous or another oral regimen

    Proportion of individuals switching off CAB+RPV LA to previous or another oral regimen after HIV-1 RNA levels of \>50 to \<400 copies/mL and \>400 copies/mL

    Time frame: Month 24

  4. Time to viral failure

    Overall time to confirmed viral failures (defined as two consecutive HIV-1 RNA ≥ 50 c/mL)

    Time frame: Up to month 24

  5. Proportion of participants who discontinue treatment due to drug-related reasons

    Proportion of participants who discontinue treatment due drug-related reasons and re-suppression regimens (such as adverse events, confirmed viral failure, low level viremia or low blood concentration measurements) including the choice of re-suppression regimens.

    Time frame: Month 24

  6. Proportion of participants who discontinue treatment due to drug-unrelated reasons

    Proportion of participants who discontinue treatment due drug-unrelated reasons and re-suppression regimens (such as patient wish, death, migration, and loss to follow-up) including the choice of re-suppression regimens.

    Time frame: Month 24

  7. Proportion of participants by characteristics

    - Proportion of participants by socio-demographic and clinical characteristic(s) (e.g., by age, sex, body mass index, race, geographic origin, education, transmission mode, HIV-1 RNA levels, CD4 cell count, duration of HIV-1 infection, HIV-1 subtype, previous regimen, genotypic resistance profile, coinfections, lifestyle variables, and co-medications)

    Time frame: Month 24

  8. Overall adherence to Swiss label indication in CAB+RPV LA prescriptions

    - Overall adherence to Swiss label indication in CAB+RPV LA prescriptions between care providers, such as university hospital versus private physicians, and among nationwide centres

    Time frame: Month 24

  9. Overall adherence to the proposed injection schedules

    - Overall adherence to the proposed injection schedules quantified by deriving an CAB+RPV LA adherence threshold (e.g., accounting for any missed injection, daily oral bridging ART, and delayed injection of +7 days according to the Swiss label indication)

    Time frame: Month 24

  10. Proportion of participants by treatment adherence category

    - Proportion of participants by treatment adherence categories (e.g., optimal, sub-optimal, and poor adherence)

    Time frame: Month 24

Secondary outcomes

  1. Investigate in-depth factors associated with viral blips and viral failure

    Proportion of individuals by risk factor(s) (e.g., by body mass index, race, geographic origin, education, HIV-1 RNA levels, CD4 cell count, duration of HIV-1 infection, HIV-1 subtype, previous regimen, treatment adherence, CAB+RPV LA plasma concentrations measured at time of failure, genotypic resistance profile , lifestyle variables, and co-medications)

    Time frame: Month 24

  2. Measure intact proviral DNA as potential predictor for viral failure

    Measure intact proviral DNA as potential predictor for viral failure among PWH initiating CAB+RPV LA regimen and compare with the matched control population on a SOC oral regimen

    Time frame: Month 24

  3. Assessment of resistance associated mutations from proviral DNA as potential predictor for viral failure

    Assessment of resistance associated mutations from proviral DNA as potential predictor for viral failure among PWH initiating CAB+RPV LA regimen and compare with the matched control population on a SOC oral regimen

    Time frame: Month 24

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Dec 2025, 45 months after the start.

Of 187 non-industry observational studies under HIV Infections, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 45 months is above that.

Counting every sponsor, half of 201 studies reached it within 38 months; a quarter within 16 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2024
First posted
May 8, 2024
StartActual
Mar 1, 2022
Primary completionEst.
Dec 31, 2025
CompletionEst.
Jun 30, 2026
Last update
May 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06405464
Collaborators
Swiss HIV Cohort Study
Responsible party
Sponsor
First posted
May 8, 2024
Start date
Mar 1, 2022
Primary completion
Dec 31, 2025 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
May 8, 2024

Study contacts

Dominique L Braun, MD
Contact
dominique.braun@usz.ch
0041442559196
Jessy J Duran Ramirez, MSc
Contact
jessy.duranramirez@usz.ch
00410446341911
Jessy J Duran Ramirez, MSc
principal investigator · Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion